Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Oyster Point Pharma stock | $10.17

Learn how to easily invest in Oyster Point Pharma stock.

Oyster Point Pharma Inc is a biotechnology business based in the US. Oyster Point Pharma shares (OYST) are listed on the NASDAQ and all prices are listed in US Dollars. Oyster Point Pharma employs 62 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Oyster Point Pharma

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OYST – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Oyster Point Pharma stock price (NASDAQ: OYST)

Use our graph to track the performance of OYST stocks over time.

Oyster Point Pharma shares at a glance

Information last updated 2021-10-23.
Latest market close$10.17
52-week range$10.70 - $25.89
50-day moving average $12.63
200-day moving average $16.21
Wall St. target price$52.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.07

Buy Oyster Point Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Oyster Point Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Oyster Point Pharma price performance over time

Historical closes compared with the close of $10.17 from 2021-10-25

1 week (2021-10-20) -20.11%
1 month (2021-09-27) -18.12%
3 months (2021-07-27) -34.00%
6 months (2021-04-27) -51.82%
1 year (2020-10-26) -51.53%
2 years (2019-10-23) N/A
3 years (2018-10-23) N/A
5 years (2016-10-23) N/A

Oyster Point Pharma financials

Gross profit TTM $0
Return on assets TTM -25.39%
Return on equity TTM -42.65%
Profit margin 0%
Book value $5.84
Market capitalisation $290.1 million

TTM: trailing 12 months

Shorting Oyster Point Pharma shares

There are currently 610,633 Oyster Point Pharma shares held short by investors – that's known as Oyster Point Pharma's "short interest". This figure is 1.2% down from 617,821 last month.

There are a few different ways that this level of interest in shorting Oyster Point Pharma shares can be evaluated.

Oyster Point Pharma's "short interest ratio" (SIR)

Oyster Point Pharma's "short interest ratio" (SIR) is the quantity of Oyster Point Pharma shares currently shorted divided by the average quantity of Oyster Point Pharma shares traded daily (recently around 100598.51729819). Oyster Point Pharma's SIR currently stands at 6.07. In other words for every 100,000 Oyster Point Pharma shares traded daily on the market, roughly 6070 shares are currently held short.

However Oyster Point Pharma's short interest can also be evaluated against the total number of Oyster Point Pharma shares, or, against the total number of tradable Oyster Point Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oyster Point Pharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Oyster Point Pharma shares in existence, roughly 20 shares are currently held short) or 0.0548% of the tradable shares (for every 100,000 tradable Oyster Point Pharma shares, roughly 55 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Oyster Point Pharma.

Find out more about how you can short Oyster Point Pharma stock.

Oyster Point Pharma share dividends

We're not expecting Oyster Point Pharma to pay a dividend over the next 12 months.

Oyster Point Pharma overview

Oyster Point Pharma, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey. .

Frequently asked questions

What percentage of Oyster Point Pharma is owned by insiders or institutions?
Currently 2.391% of Oyster Point Pharma shares are held by insiders and 89.563% by institutions.
How many people work for Oyster Point Pharma?
Latest data suggests 62 work at Oyster Point Pharma.
When does the fiscal year end for Oyster Point Pharma?
Oyster Point Pharma's fiscal year ends in December.
Where is Oyster Point Pharma based?
Oyster Point Pharma's address is: 202 Carnegie Center, Princeton, NJ, United States, 08540
What is Oyster Point Pharma's ISIN number?
Oyster Point Pharma's international securities identification number is: US69242L1061
What is Oyster Point Pharma's CUSIP number?
Oyster Point Pharma's Committee on Uniform Securities Identification Procedures number is: 69242L106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site